Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

We also continue to make exciting progress on the regulatory front, with approvals in the quarter for both sickle cell disease and TDT in Switzerland and Canada. And in the Middle East ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

The company's progress in this field is the biggest reason it has generally performed well in the past 10 years: VRTX Revenue (Quarterly ... On the regulatory front, Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a listen-only mode. [Operator instructions] After today's presentation, there will ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

While there are several candidates to make the next stock split announcement, Vertex Pharmaceuticals (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4. Just because a stock ...